Plasma Products

Restivo, Joseph S.A.; Karafin, Matthew S.

doi:10.1016/b978-0-12-813726-0.00034-9

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While positivity for antibodies to SARS-CoV-2 was documented using the NYSDOH Luminex-based assay, titers were not available and may influence outcomes [19]. Plasma contains numerous other proteins, including soluble clotting factors such as fibrinogen, factor XIII, von Willebrand factor (VWF), and vitamin K-dependent coagulation factors II, VII, IX, and X. Fibrinolytic proteins are also contained at normal physiologic concentrations [20,21]. The effect of these other factors in our patient population who received treatment with CCP is unknown and may have contributed to observed outcomes.…”

Section: Discussionmentioning

confidence: 99%

Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients

Klapholz

Pentakota

Zertuche

et al. 2021

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The utility of convalescent COVID-19 plasma (CCP) in the current pandemic is not well defined. We sought to evaluate safety and efficacy of CCP in severely or life threateningly ill COVID-19 patients when matched with a contemporaneous cohort. Methods Patients with severe or life threatening COVID-19 were treated with CCP according to FDA criteria, prioritization by an interdisciplinary team and based on CCP availability. Individual-level matched controls (1:1) were identified from patients admitted during the prior month when no CCP was available. Safety outcome was freedom from adverse transfusion reaction and efficacy outcome a composite of death or worsening O2 support. Demographic, clinical and laboratory data were analyzed by univariate and multivariable regression analyses accounting for matched design. Results Study patients (N=94, 47 matched pairs) were 62% male with mean age of 58 and 98% (90/94) were minority (53% Hispanic, 45% Black, non-Hispanic) in our inner-city population. Seven-day composite and mortality outcomes suggested a non-significant benefit in CCP treated patients (adjusted hazard ratio (aHR), 0.70; 95% confidence interval (CI), 0.23 to 2.12; P=0.52; aHR, 0.23; 95% CI, 0.04 to 1.51; P=0.13, respectively). Stratification by pre-transfusion mechanical ventilation status showed no differences between groups. No serious transfusion reactions occurred. Conclusion In this short-term matched cohort study, transfusion with CCP was safe and showed a non-significant association with study outcomes. Randomized and larger trials to identify appropriate timing and dosing of CCP in COVID-19 is warranted. Trial Registration: ClinicalTrials.gov Identifier: NCT04420988

show abstract

Section: Discussionmentioning

confidence: 99%

Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients

Klapholz

Pentakota

Zertuche

et al. 2021

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

Galli

Bruschi

2020

The EuroBiotech Journal

View full text Add to dashboard Cite

Around 70 infectious agents are possible threats for blood safety.The risk for blood recipients is increasing because of new emergent agents like West Nile, Zika and Chikungunya viruses, or parasites such as Plasmodium and Trypanosoma cruzi in non-endemic regions, for instance.Screening programmes of the donors are more and more implemented in several Countries, but these cannot prevent completely infections, especially when they are caused by new agents.Pathogen inactivation (PI) methods might overcome the limits of the screening and different technologies have been set up in the last years.This review aims to describe the most widely used methods focusing on their efficacy as well as on the preservation integrity of blood components.

show abstract

Plasma Products

Cited by 2 publications

References 10 publications

Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients

Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients

New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

Contact Info

Product

Resources

About